Gabapentin Withdrawal Presenting as Status Epilepticus

REFERENCES

• Appleton R., Fichtner K., LaMoreaux L., Alexander J., Halsall G., Murray G., Garofalo E. Gabapentin as Add-On Monotherapy in Children with Refractory Partial Seizures: A 12-Week, Multi-centre, Double-Blind, Placebo-Controlled Study. Epilepsia 1999; 40(8)1147–1154
   PubMed Web of Science ®Google Scholar
• Beydoun A., Fischer J., Labar D.R., Harden C., Cantrell D., Uthman B.M., Sackellares J.C., Abou-Khalil B., Ramsay R.E., Hayes A., Greiner M., Garofalo E., Pierce M. Gabapentin Monotherapy: II. A 26-Week, Double-Blind, Dose-Controlled, Multicenter Study of Conversion from Polytherapy in Outpatients with Refractory Complex Partial or Secondarily Generalized Seizures. The US Gabapentin Study Group 82/83. Neurology 1997; 49(3)746–752
   PubMed Web of Science ®Google Scholar
• Mathew N.T., Rapoport A., Saper J., Magnus L., Klapper J., Ramadan N., Stacey B., Tepper S. Efficacy of Gabapentin in Migraine Prophylaxis. Headache 2001; 41(2)119–128
   PubMed Web of Science ®Google Scholar
• Leandri M., Luzzani M., Cruccu G., Gottlieb A. Drug-Resistant Cluster Headache Responding to Gabapentin: A Pilot Study. Cephalalgia 2001; 21(7)744–746
   PubMed Web of Science ®Google Scholar
• De Leon O.A. Antiepileptic Drugs for the Acute and Maintenance Treatment of Bipolar Disorder. Harv. Rev. Psychiatry 2001; 9(5)209–222
   PubMed Web of Science ®Google Scholar
• Devulder J., Lambert J., Naeyaert J.M. Gabapentin for Pain Control in Cancer Patients' Wound Dressing Care. J. Pain Symptom Manag. 2001; 22(1)622–626
   PubMed Web of Science ®Google Scholar
• Rice A.S., Maton S. Gabapentin in Postherpetic Neuralgia: A Randomized, Double Blind, Placebo Controlled Study. Pain 2001; 94(2)215–224
   PubMed Web of Science ®Google Scholar
• Maneuf Y.P., McKnight A.T. Block by Gabapentin of the Facilitation of Glutamate Release from Rat Trigeminal Nucleus Following Activation of Protein Kinase C or Adenylyl Cyclase. Br. J. Pharmacol. 2001; 134(2)237–240
   PubMed Web of Science ®Google Scholar
• Taylor C.P., Gee N.S., Su T.Z., Kocsis J.D., Welty D.F., Brown J.P., Dooley D.J., Boden P., Singh L. A Summary of Mechanistic Hypotheses of Gabapentin Pharmacology. Epilepsy Res. 1998; 29(3)233–249
   PubMed Web of Science ®Google Scholar
• Stefani A., Spadoni F., Giacomini P., Lavaroni F., Bernardi G. The Effects of Gabapentin on Different Ligand- and Voltage-Gated Currents in Isolated Cortical Neurons. Epilepsy Res. 2001; 43(3)239–248
   PubMed Web of Science ®Google Scholar
• Langan Y., Duncan J.S., Sander J.W. An Audit of the Perceived Efficacy and Tolerability of Gabapentin Therapy in an Out-Patient Cohort with Chronic Epilepsy. Eur. Neurol. 1999; 41(2)111–113
   PubMed Web of Science ®Google Scholar
• Fisher R.S., Schdeo R.C., Pellock J., Penovich P.E., Magnus L., Bernstein P. Rapid Initiation of Gabapentin. Neurology 2001; 56(6)743–748
   PubMed Web of Science ®Google Scholar
• Wilson E.A., Sill G.J., Forrest G., Brodie M.J. High Dose Gabapentin in Refractory Partial Epilepsy: Clinical Observations in 50 Patients. Epilepsy Res. 1998; 29(2)161–166
   PubMed Web of Science ®Google Scholar
• Norton J.W. Gabapentin Withdrawal Syndrome. Clin. Neuropharmacol. 2001; 24(4)245–256
   PubMed Web of Science ®Google Scholar
• Cora-Locatelli G., Greenberg B.D., Martin J.D., Murphy D.L. Rebound Psychiatric and Physical Symptoms After Gabapentin Discontinuation. J. Clin. Psychiatry 1998; 59(3)131
   PubMed Web of Science ®Google Scholar
• Rosebush P.I., MacQueen G.M., Mazurek M.F. Catatonia Following Gabapentin Withdrawal. J. Clin. Psychopharmacol. 1999; 19(2)188–189
   PubMed Web of Science ®Google Scholar
• Stringer J.L., Lorenzo N. The Reduction in Paired-Pulse Inhibition in the Rat Hippocampus by Gabapentin is Independent of GABA(B) Receptor Activation. Epilepsy Res. 1999; 33(2–3)169–170
   PubMed Web of Science ®Google Scholar
• Petroff O.A.C., Rothman D.L., Behar K.L., Lamoureux D., Mattson R.H. The Effect of Gabapentin on Brain Gamma-Aminobutyric Acid in Patients with Epilepsy. Ann. Neurol. 1996; 39(1)95–99
   PubMed Web of Science ®Google Scholar
• Bertrand S., Ng G.Y.K., Purisai M.G., Wolfe S.E., Severidt M.W., Nouel D., Robitaille R., Low M.J., O'Neill G.P., Metters K., Lacaille J.C., Chronwall B.M., Morris S.J. The Anticonvulsant, Antihyperalgesic Agent Gabapentin is an Agonist at Brain γ-Aminobutyric Acid Type B Receptors Negatively Couple to Voltage-Dependent Calcium Channels. J. Pharmacol. Exp. Ther. 2001; 298(1)15–24
   PubMed Web of Science ®Google Scholar
• Ng G.Y.K., Bertrand S., Sullivan R., Ethier N., Wang J., Yergey J., Belley M., Trimble L., Bateman K., Alder L., Smith A., McKernan R., Metters K., O'Neill G.P., Lacaille J.C., Hebert T.E. γ-Aminobutyric Acid Type B Receptors with Specific Heterodimer Composition and Postsynaptic Actions in Hippocampal Neurons Are Targets of Anticonvulsant Gabapentin Action. Mol. Pharmacol. 2001; 59(1)144–152
   PubMed Web of Science ®Google Scholar
• Bonnet U., Banger M., Leweke F.M., Maschke M., Kowalski T., Gastpar M. Treatment of Alcohol Withdrawal Syndrome with Gabapentin. Pharmacopsychiatry 1999; 32(3)107–109
   PubMed Web of Science ®Google Scholar
• Tomson T., Johannessen. Therapeutic Monitoring of the New Antiepileptic Drugs. Eur. J. Clin. Pharmacol. 2000; 55(10)697–705
   PubMed Web of Science ®Google Scholar